SPRY — ARS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $429.61m
- $382.44m
- $84.28m
ARS Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
ARS rises on positive trial result for urticaria treatment
Brief: ARS Pharmaceuticals Announces Neffy Meets Primary Endpoints And Shows Rapid Symptom Control In Phase 2 urticaria Clinical Study
U.S. RESEARCH ROUNDUP-Home Depot, Palo Alto Networks, Wendys
U.S. STOCKS ON THE MOVE-Barrick Gold, Western Midstream, ARS Pharma
ARS Pharma rises on positive results from repeat dose study of nasal spray
Brief: ARS Pharmaceuticals To Present Positive Clinical Efficacy Data For Neffy At 2024 Aaaai Annual Meeting
ARS Pharma rises on smaller-than-expected Q3 loss
Brief: ARS Pharmaceuticals Q3 basic EPS USD -0.16
ARS Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Frontdoor, gold miners, UniFirst
U.S. STOCKS ON THE MOVE-ARS Pharma, AMC, Eli Lilly
Brief: Ars Pharmaceuticals Announces Scheduling Of A Type A Meeting With The U.S. FDA For Neffy® (Epinephrine Nasal Spray)
ARS Pharma schedules Type A meeting with FDA for allergy drug; shares rise
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx
U.S. STOCKS ON THE MOVE-Lululemon, Copper miners, Gold miners
Nasal spray alternative to EpiPen faces setback as FDA seeks fresh study (updated)